Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, PubMed:30061385, PubMed:34646012, PubMed:34819673). Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). Following activation by ALKAL2 ligand at the cell surface, transduces an extracellular signal into an intracellular response (PubMed:30061385, PubMed:33411331, PubMed:34646012, PubMed:34819673). In contrast, ALKAL1 is not a potent physiological ligand for ALK (PubMed:34646012). Ligand-binding to the extracellular domain induces tyrosine kinase activation, leading to activation of the mitogen-activated protein kinase (MAPK) pathway (PubMed:34819673). Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif (PubMed:15226403, PubMed:16878150). Induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1 (PubMed:15226403, PubMed:16878150). ALK activation may also be regulated by pleiotrophin (PTN) and midkine (MDK) (PubMed:11278720, PubMed:11809760, PubMed:12107166, PubMed:12122009). PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation (PubMed:11278720, PubMed:11809760, PubMed:12107166). MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction (PubMed:12122009). Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase (PubMed:15226403, PubMed:16878150). Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK (PubMed:15226403, PubMed:16878150). May function as regulator of gastric epithelial differentiation (By similarity). {ECO:0000250|UniProtKB:P97793, ECO:0000269|PubMed:11121404, ECO:0000269|PubMed:11278720, ECO:0000269|PubMed:11387242, ECO:0000269|PubMed:11809760, ECO:0000269|PubMed:12107166, ECO:0000269|PubMed:12122009, ECO:0000269|PubMed:15226403, ECO:0000269|PubMed:16317043, ECO:0000269|PubMed:16878150, ECO:0000269|PubMed:17274988, ECO:0000269|PubMed:30061385, ECO:0000269|PubMed:33411331, ECO:0000269|PubMed:34646012, ECO:0000269|PubMed:34819673}.
Chromosome
2
Biotype
protein_coding
Diseases
25
Variants
0
Also Known As
25 disease associations found
| Disease | Score | Therapeutic Areas |
|---|---|---|
| neuroblastoma | 0.84 | nervous system disordercancer or benign tumor |
| neuroblastoma, susceptibility to, 3 | 0.76 | genetic, familial or congenital diseasecancer or benign tumor |
| non-small cell lung carcinoma | 0.76 | respiratory or thoracic diseasecancer or benign tumor |
| cancer | 0.73 | cancer or benign tumor |
| neoplasm | 0.66 | cancer or benign tumor |
| lung cancer | 0.54 | respiratory or thoracic diseasecancer or benign tumor |
| anaplastic large cell lymphoma | 0.51 | hematologic disordercancer or benign tumor |
| lung adenocarcinoma | 0.49 | cancer or benign tumorrespiratory or thoracic disease |
| squamous cell lung carcinoma | 0.47 | respiratory or thoracic diseasecancer or benign tumor |
| lymphoma | 0.47 | hematologic disordercancer or benign tumor |
| inflammatory myofibroblastic tumor | 0.43 | cancer or benign tumor |
| hereditary neoplastic syndrome | 0.42 | genetic, familial or congenital diseasecancer or benign tumor |
| Inherited cancer-predisposing syndrome | 0.42 | genetic, familial or congenital disease |
| ovarian cancer | 0.42 | endocrine system disorderreproductive system or breast diseasecancer or benign tumor |
| lung carcinoma | 0.40 | respiratory or thoracic diseasecancer or benign tumor |
12 drugs targeting this gene
ALK tyrosine kinase receptor inhibitor
ALK tyrosine kinase receptor inhibitor
EML4-ALK inhibitor
ALK tyrosine kinase receptor inhibitor
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor
EML4-ALK inhibitor
ALK tyrosine kinase receptor inhibitor
ALK tyrosine kinase receptor inhibitor
ALK tyrosine kinase receptor inhibitor
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.